PDCD1
protein-codingprogrammed cell death 1, the group of V-set domain containing|CD molecules
Gene summary
Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity. [provided by RefSeq, Aug 2020]
- SLEB2
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~9.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: Unknown
Disease ID:MONDO:0007915
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0007179
Submitter: ClinGen
The *PDCD1* gene codes programmed cell death protein (PD-1), which is an immune-inhibitory receptor expressed in activated T cells. The PD1 protein is involved in the regulation of T-cell functions and the differentiation of CD4+ T cells into T regulatory cells. In 2021, Ogishi et al identified a homozygous frameshift variant of *PDCD1* c.105dup (p.Thr36HisfsTer) in a child born to consanguineous Turkish parents. The patient suffered from extrapulmonary tuberculosis and autoimmune manifestations including hypothyroidism, diabetes and juvenile idiopathic arthritis with autoimmune antibody positivity. The patient’s leukocytes did not express PD-1 and showed impaired production of IFN-γ and TNF upon mycobacterial stimulation, a similarity to inborn errors of IFN-γ production (PMID: 34183838). In addition to the expression evidence, several animal models recapitulated the phenotype observed in the reported proband and exhibited various degrees of lympho-proliferation and autoimmune disease (PMIDs: 10485649,12847137, 20410257, 27410049). Programmed death-1 (PD-1)-deficient mice showed sensitivity to tuberculosis demonstrated by increased bacterial loads and extensive focal necrotic areas after H37Rv aerosol infection, compared with wild-type mice (PMID: 20624978). It is worth mentioning that PD-1 and its ligand PD-L1, are used as drug targets to develop immune checkpoint blockade therapies for cancer. A series of immune-related adverse events (irAEs) which mimic the autoimmune phenotype reported are induced (PMIDs: 26176400, 35991054 , 37715029). Vulnerability to TB are also reported in cancer patients and macaques on PD-1 blockade (PMIDs: 30651320, 33452107). While there is multiple lines of evidence that fulfilled the experimental maximum score of 6 points, the genetic evidence stood at 2 points because there is a single proband reported at the time of this curation. Therefore, the evidence to support this gene-disease relationship is limited. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship.
Inheritance Pattern: AR
Disease ID:MONDO:0975847
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious
Intervention: Allergy/Immunology/Infectious
Rationale: The condition can involve susceptibility to mycobacterium tuberculosis, and awareness may enaable preventative measures and early and aggressive treatments of infections, as well as care related to autoimmune manifestations
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PDCD1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005018.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 1 | 4 | |||
| missense | 14 | 2 | 16 | |||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 0 | 0 | 15 | 5 | 1 | 21 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005009.2 | 5 | MANE Select | |
| Ensembl | ENSP00000335062.5 | 5 | MANE Select | |
| Ensembl | ENSP00000340808.3 | 3 | Standard | |
| Ensembl | ENSP00000340808.4 | 4 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Cell adhesion molecules (CAMs) - Homo sapiens (human)
- T cell receptor signaling pathway - Homo sapiens (human)
- T-Cell Receptor and Co-stimulatory Signaling
- T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection
- PD-1 signaling
Biological Process
- negative regulation of tolerance induction
- apoptotic process
- humoral immune response
- multicellular organism development
- T cell costimulation
Molecular Function
- protein binding
Cellular Component
- plasma membrane
- external side of plasma membrane
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000334409
- Coding exons
- 5
- Length
- 9028
- Individuals with no LoFs
- 0
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 0
- Defined
- 0
- p
- 0.00
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.29 | 139 | 189 | 0.735 | 0.0000127 | 1823 |
| Missense (PolyPhen) | 25 | 52.205 | 0.47889 | 581 | ||
| Synonymous | 0.670 | 75 | 82.8 | 0.906 | 0.00000592 | 619 |
| Loss of Function | 2.26 | 2 | 9.51 | 0.210 | 4.10e-7 | 92 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen- specific manner. Possible cell death inducer, in association with other factors. {ECO:0000269|PubMed:21276005}.;
- Disease
- DISEASE: Systemic lupus erythematosus 2 (SLEB2) [MIM:605218]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. {ECO:0000269|PubMed:12402038}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.278
Intolerance Scores
- LoFtool
- 0.458
- RVIS EVS
- -0.31
- RVIS percentile EVS
- 31.93
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.456
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |